deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT02409368

An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC (Checkmate 171)

Sponsor: Bristol-Myers Squibb

Interventions Nivolumab
Updated 22 times since 2017 Last updated: Oct 17, 2022 Started: Apr 29, 2015 Primary completion: Mar 7, 2018 Completion: Aug 27, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02409368, this PHASE2 trial focuses on Non-Small Cell Lung Cancer and remains completed. Sponsored by Bristol-Myers Squibb, it has been updated 22 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Jul 2017 · 2 months · monthly snapshot~Jul 2017 – ~Aug 2017 · 31 days · monthly snapshot~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Nov 2017 · 2 months · monthly snapshot~Nov 2017 – ~Dec 2017 · 30 days · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Nov 2019 · 12 months · monthly snapshot~Nov 2019 – ~Jul 2020 · 8 months · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Jan 2022 · 2 months · monthly snapshot~Jan 2022 – ~Dec 2022 · 11 months · monthly snapshot~Dec 2022 – ~Jul 2024 · 19 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Jun 2025 · 8 months · monthly snapshot~Jun 2025 – ~Sep 2025 · 3 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

22 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Jun 2025 — Sep 2025 [monthly]

    Completed PHASE2

  3. Oct 2024 — Jun 2025 [monthly]

    Completed PHASE2

  4. Sep 2024 — Oct 2024 [monthly]

    Completed PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

Show 17 earlier versions
  1. Dec 2022 — Jul 2024 [monthly]

    Completed PHASE2

  2. Jan 2022 — Dec 2022 [monthly]

    Completed PHASE2

  3. Nov 2021 — Jan 2022 [monthly]

    Completed PHASE2

    Status: Active Not RecruitingCompleted

  4. Sep 2021 — Nov 2021 [monthly]

    Active Not Recruiting PHASE2

  5. Jan 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

  6. Jul 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  7. Nov 2019 — Jul 2020 [monthly]

    Active Not Recruiting PHASE2

  8. Nov 2018 — Nov 2019 [monthly]

    Active Not Recruiting PHASE2

  9. Jun 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE2

  10. Dec 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  11. Nov 2017 — Dec 2017 [monthly]

    Active Not Recruiting PHASE2

  12. Sep 2017 — Nov 2017 [monthly]

    Active Not Recruiting PHASE2

  13. Aug 2017 — Sep 2017 [monthly]

    Active Not Recruiting PHASE2

  14. Jul 2017 — Aug 2017 [monthly]

    Active Not Recruiting PHASE2

  15. May 2017 — Jul 2017 [monthly]

    Active Not Recruiting PHASE2

  16. Feb 2017 — May 2017 [monthly]

    Active Not Recruiting PHASE2

  17. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Apr 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • PPD Development, LP
Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .